Table 2.

Patients who can be considered for a switch to direct oral anticoagulants.

Probably	Probably not
Stable metastatic cancer on oral or maintenance intravenous treatment Metastatic cancer stable post immunotherapy treatment Metastatic malignancy with expected long survival (ER + breast cancer on oral agent, low-grade lymphoma)	Metastatic cancer on immunotherapy treatment Metastatic cancer progressing on treatment Metastatic malignancy with expected short survival (pancreatic cancer, esophageal cancer, and refractory high-grade lymphoma)